KRAS and non-small cell lung carcinoma: We demonstrate that KRAS mutants induce chemoresistance in NSCLC by amplifying EKR/JNK signaling-mediated ALKBH5 posttranslational modifications (PTMs), including phosphorylation and SUMOylation.